Unter diesem Titel wurde am 6.7. auf uncutnews.ch eine Analyse vonYaffa Shir-Raz, PhD, veröffentlicht (dort ohne Anführungszeichen). Shir-Raz ist Forscherin im Bereich Risikokommunikation und Lehrbeauftragte an der Universität Haifa und dem Interdisciplinary Center Herzliya in Israel.
Sie verweist auf die vier Kinder unter den 1.131 "geimpften", für die schwerwiegende unerwünschte Ereignisse gemeldet wurden. Drei von ihnen mußten wegen schwerer Depressionen einige Tage nach der "Impfung" in Krankenhäusern behandelt werden. Wenig beruhigend ist die Erklärung von Pfizer, daß bei den Kindern schon zuvor entsprechende Diagnosen bestanden hatten. Sie hätten damit selbst nach dem eigenen Studienprotokoll gar nicht in die Studie aufgenommen werden dürfen. "Verschlimmernde Suizidgedanken" seien bei der Behandlungsart der vorbelasteten Kinder ein "anerkanntes Risiko", so Pfizer.
Shir-Raz vermutet weiter, daß schwerwiegende unerwünschte Ereignisse, die nach einem Beobachtungszeitraum von 30 Tagen auftreten, in der Studie nicht vermeldet werden.
Darüber hinaus interpretiert sie eine Formulierung im Studienprotokoll so, daß ärztliche Diagnosen nicht berücksichtigt würden, die außerhalb des Forschungsstandorts gestellt werden. Erkenntnisse von Erkrankungen, die in anderen Krankenhäusern anfielen, würden so ggf. nicht in die Ergebnisse einfließen.
Pfizer hat doch hervoragende Antidepressiva im Angebot, die einen in den Selbstmord treiben können.
https://www.idc.ac.il/en/pages/faculty.aspx?username=Yaffa.ShirRaz
"Ihre Schwerpunkte in Forschung und Lehre liegen in den Bereichen Gesundheits- und Risikokommunikation, Gesundheits-PR und persuasive Kommunikation. Dabei konzentriert sie sich vor allem auf kontroverse Themen, die mit Unsicherheit verbunden sind.
Sie untersucht die Strategien und Taktiken von Pharmaunternehmen zur Bewerbung von Medikamenten und damit die Frage, wie Gesundheitsrisiken im Zusammenhang mit Krankheiten und Medikamenten von dieser Industrie kommuniziert werden und wie Behörden diese Werbemaßnahmen regulieren.
Darüber hinaus konzentriert sich ihre Forschung auf die Gesundheits- und Risikokommunikation während Epidemien (EID-Kommunikation), durchgeführt im Rahmen der Forschungsprojekte TELL ME und ASSET, die beide von der Europäischen Kommission finanziert werden.
Sie ist außerdem leitende Gesundheitsjournalistin für das Menta Magazine, Yedioth Aharonot, Israel, und hat sich in den letzten 15 Jahren auf investigativen Journalismus konzentriert."
"Schwere Verstöße und Manipulationen des Studienprotokolls: Wie Pfizer die FDA-Notfallgenehmigung für Kinder erhielt"
Wer mir jetzt immer noch erzählen will, dass dies doch gar nichts mit den Versuchen der 30er Jahre zu tun hat, dem kann ich nicht helfen.
Für mich ist es ein bewußtes Inkaufnehmen von schweren geistigen und körperlichen Nebenwirkungen, jetzt sogar auch bei Kindern. Es wird sogar der Tod in Kauf genommen.
Diesem Gesindel ist alles erlaubt; sie werden auch niemals zur Rechenschaft gezogen und wir wissen nicht, was die noch so alles in petto haben.
Das wußte man damals auch nicht.
Dr. Robert Malone (Erfinder der mRNA- Methode) zu den unerforschten Vakzin- Risiken⚠️ und der groben Fahrlässigkeit der Zulassungsbehörden bei der Prüfung der Impfstoffe vor Anwendung in der breiten Bevölkerung! https://alschner-klartext.de/2021/07/03/die-zulassungsbehoerden-haben-keinen-blassen-schimmer/
die Studien waren immer gefälscht. siehe Timiflu, von Roche! Negative Ergebnisse werden weggelassen, um eine Notfall Genehmigung mit korrupte Institutionen zu erhalten
@D.D. vielen Dank für den Link, UNFASSBAR!! Der Bericht sollte auf der Titelseite einer großen Tageszeitung veröffentlicht werden, aber ich schätze, dann können die einpacken! Warum eigentlich??
Oder, evtl. kopieren und den in diesem Lande für die Impfung verantwortlichen "POLITIKERN"( ha, ha,) als "denkauffrischenden" Einschreibebrief senden, wenn´s denn ankommt.…
@Lucy: auch hier noch der Link (Dr. R. Malone) für das entsprechende Video zum Link von D.D.
https://www.youtube.com/watch?v=PA8nq3lqP1s
Das "Design" der Studien zwecks erfolgreicher Zulassung wird doch geradezu von den weltweit operierenden Corona-Regimen implizit gefordert. Es muss ein "Impfstoff" her. Absprachen zwischen der forschenden Pharmaindustrie und den weltweit operierenden Corona-Regierungen existieren wohl zwangsläufig. Der implizite Druck auf regulatorische Behörden zur Zulassung ist das Resultat. Man hat ja Plandemie. Wann, wenn nicht jetzt kann diese Technologie getestet werden ohne finanzielle Risiken und größere ethische Bedenken.
Depressionen? Ende Juni 2021:
"Ein Mutter aus Ohio spricht über ihre 12-jährige Tochter, die unter extremen Reaktionen leidet und fast gestorben wäre durch Teilnahme an der Pfizer Coronavirus-Impfstoff-Studie.
Stephanie De Garay sagte 'Tucker Carlson Tonight' am Donnerstag, dass nach Auskunft mehrere Ärzte, Maddie De Garay nicht durch den Impfstoff schwer krank geworden sein könne.
'Die einzige Diagnose, die wir für sie bekommen haben, ist, dass es Konversionsstörung oder funktionelle neurologische Symptomstörung ist, und sie schieben es auf Angst,' sagte de Garay Tucker Carlson. …"
https://www.foxnews.com/media/ohio-woman-daughter-covid-vaccine-reaction-wheelchair
◦
26.10.2021
FDA
VRBPAC
Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document
BNT162b2
VRBPAC Briefing Document
BNT162B2 [COMIRNATY (COVID-19 VACCINE, MRNA)]
Page 11
Overall Risk-Benefit Conclusions
COVID-19 continues to be a serious and potentially fatal or life-threatening infection for children and there is a significant unmet medical need in the 5 to <12 years of age population.
Two primary doses of the 10 μg BNT162b2 vaccine given 3 weeks apart in 5 to <12 years of age have shown a favorable safety and tolerability profile, robust immune responses against all variants of concern and high VE against symptomatic COVID-19 in a period where the delta variant was predominant.
The number of participants in the current clinical development program is too small to detect any potential risks of myocarditis associated with vaccination. Long-term safety of COVID-19 vaccine in participants 5 to <12 years of age will be studied in 5 post-authorization safety studies, including a 5‑year follow-up study to evaluate long term sequelae of post-vaccination myocarditis/pericarditis.
https://www.fda.gov/media/153409/download
◦
· Ceterum censeo COVAX delendam esse ·
◦
17.09.2021 • U.S. Food and Drug Administration • FDA
Vaccines and Related Biological Products Advisory Committee – 9/17/2021
[ VRBPAC Meeting ]
(Join us for a Vaccines and Related Biological Products Advisory Committee meeting to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older.)
[ h 8:09.40 ] [ Beinahe acht Stunden und zehn Minuten ist hier das VRBPAC Meeting / Advisory Committee Meeting vom 17. September 2021 dokumentiert. Ab h 4:20:10 Steve Kirsch. ]
h 4:20:28
Steve Kirsch:
« I'm going to focus my remarks today on the elephant in the room that nobody likes to talk about—that the vaccines kill more people than they save. Today we focus almost exclusively on COVID death saves and vaccine efficacy—because we were led to believe that vaccines are perfectly safe. But this is simply not true. For example there are four times as many heart attacks in the treatment group in the Pfizer six-month trial report—that wasn't bad luck. VAERS shows heart attack happened 71 times more often following these vaccines compared to any other vaccine. In all 20 people died, who got the drug, 14 died who got the placebo. Few people notice that, if the net all-cause mortality from the vaccines is negative, vaccines, boosters, and mandates are all nonsensical—this is the case today. »
« Death rates. This shows that the all-cause death light rate and, in three cases, only the VAERS numbers are statistically significant, but the other numbers are troubling. Even if the vaccines had 100% protection, it still means we killed two people to save one life. Four experts did analyses using completely different Non‑U.S. data sources, and all of them came up with approximately the same number of excess vaccine-related deaths, about 411 deaths per million doses. That translates into 150,000 people have died. Now the real numbers confirm that we kill more than we save. And I would love everyone to look at the Israel Ministry of health data on the 90 plus-year-olds where we went from a 94.4% vaccinated group to 82.9% vaccinated in the last four months. In the most optimistic scenario, it means that 50% of the vaccinated people died, and 0% of unvaccinated people died. Unless you can explain that to the American public—you cannot approve the boosters. »
— Steve Kirsch, Executive Director of COVID-19 Early Treatment Fund · CETF
https://www.youtube.com/watch?v=WFph7-6t34M
◦
Advisory Committee Meeting
Vaccines and Related Biological Products Advisory Committee September 17, 2021 Meeting Announcement
September 17, 2021
https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-september-17–2021-meeting-announcement
◦
· Ceterum censeo COVAX esse delendam ·
፨
22.10.2020 / 22. Oktober 2020 / October 22, 2020
[ VRBPAC-Treffen Nummer 161 ]
161st Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting
Sheldon Toubman, J.D. New Haven Legal Assistance Association
Doran Fink, M.D., Ph.D. Food and Drug Administration
Marion Gruber, Ph.D. Food and Drug Administration
Arnold Monto, Professor of Public Health and Epidemiology at the University of Michigan School of Public Health
Robert Johnson * , Ph.D. BARDA
Hilary Marston ** , M.D., M.P.H. NIAID & NIH
MR. TOUBMAN:
(…) Two questions related for Dr. Fink specifically. Two related to either licensure or EUA, and one specifically to EUA. (…)
So my question is, why would that not require the primary endpoint is serious disease?
The second question (…) we read about the 50 percent and it was repeated again today. But this morning, Dr. Marston from NIH said—and, you know, Dr. Monto followed up on that, that 60 percent (…)
And then my last question related to EUA is, this came up in the public hearing as well, two months. (…) explanation we were told that the document says that most of the adverse effects occur in the first six weeks. But they could be longer than that and we’re talking about drugs based on untested, or I should say unused platforms that have never been the basis for vaccines.
So there could be adverse effects we don’t know about. And so isn’t two months a little short? (…)
fda.gov/media/143982/download
፨
( 161st Meeting )
( 161. Treffen )
SUMMARY MINUTES
(…)
On October 22, 2020 at 10:00 a.m. Eastern Standard Time (EST), the 161st Meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in open session to discuss, in general, the development, authorization and/or licensure of vaccines to prevent COVID-19. No specific application was discussed at this meeting.
Dr. Arnold Monto, the Acting Chair, called the meeting to order. The DFO made administrative remarks, conducted roll call and invited the committee members to introduce themselves, and read the Conflict of Interest (COI) statement into the public record. It was stated that two conflict of interest waivers were issued under 18 U.S. Code 208 in connection with the meeting and the waivers were posted on the FDA website for public disclosure.
Dr. Marion Gruber of FDA provided an introductory presentation titled “Development, Authorization & Licensure of Vaccines to Prevent COVID-19.” This was followed by a presentation by Dr. Cliff McDonald from the Centers for Disease Control and Prevention (CDC) entitled, „Epidemiology, Virology, and Clinical Features of COVID-19.” Following Dr. McDonald’s presentation was an overview presentation by Dr. Hilary Marston titled ‘COVID-19 Vaccine Development: The Role of the NIH.’ Once her presentation concluded, Dr. Robert Johnson with BARDA presented ‘COVID-19 Vaccine Development Portfolio.’
After a 10-minute break, Dr. Tom Shimabukuro and Dr. Stephanie Schrag with CDC gave a joint presentation on “CDC plans for Vaccine Safety and Effectiveness monitoring & evaluation during future EUA use and post licensure.” Following their presentation, Dr. Steven Anderson with the FDA presented on ‘CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness. Then CAPT. Janell Routh from CDC presented on ‘COVID-19 Vaccine Implementation: Operational aspects of COVID-19 vaccine distribution and tracking.’
After a 30-minute lunch break, the presentations continued, resuming with ‘COVID-19 Vaccine Confidence’ presented by Ms. Susan Winckler and Dr. Wilks, both with the Reagan-Udall Foundation. Dr. Weir with FDA then presented ‘Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19: Chemistry, Manufacturing, and Controls (CMC) Considerations.’ The last Agency presentation in the afternoon was by Dr. Doran Fink with FDA titled ‘Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19: Clinical Considerations.’
fda.gov/media/143983/download
፨
13.02.2020
* Robert Johnson
Development of Medical Countermeasures for 2019-Novel Coronavirus
Robert Johnson, PhD
Director, Division of Influenza and Emerging Infectious Diseases
BARDA/ASPR/HHS
National Vaccine Advisory Committee, 2/13/2020
Abbreviations / Einige Abkürzungen erklärt
BARDA = Biomedical Advanced Research and Development Authority
ASPR = Assistant Secretary for Preparedness and Response
HHS > The Office of the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS)
EZ-BAA [ Beispielsatz ] This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR).
ENACT
DRIVe [ Textbeispiel ] BARDA’s Division of Research, Innovation, and Ventures (DRIVe) today expanded the Early Notification to Act, Control, and Treat (ENACT) program to drive disruptive technologies needed to save lives in future public health emergencies. To solicit potential partners, DRIVe opened two new areas of interest (AOI) under the EZ Broad Agency Announcement (EZ-BAA) solicitation: Digital Health Tools for Pandemic Preparedness and Bringing Laboratory Testing to the Home. In 2018, DRIVe explored early detection of respiratory infections with the launch of ENACT, partnering with innovators to develop disruptive technologies that could detect infection and enable early intervention prior to symptom onset. These technologies included both biophysical and digital health solutions coupled with data analytics approaches to assess early infection status of an individual as well as within a population.
medicalcountermeasures.gov/newsroom/2021/driveaoi14/
hhs.gov/sites/default/files/nvac_feb2020_day1_johnson.pdf
፨
** Hilary Marston
Dr. Marston was a panelist for the Forum’s discussions on The Coronavirus Outbreak.
Hilary Marston, MD, MPH is a Medical Officer and Policy Advisor for Global Health focusing on emerging infectious disease preparedness and response. In this role, she coordinates the National Institute of Allergy and Infectious Diseases’ response to outbreaks including Zika in the Americas and Ebola in West Africa and the Democratic Republic of the Congo. Dr. Marston trained in internal medicine at Brigham & Women’s Hospital, during which time she worked with Partners in Health and the Clinton Health Access Initiative. Before her medical training, Dr. Marston worked for McKinsey & Company and at the Bill & Melinda Gates Foundation as a Program Officer and Special Assistant to the Co-Chair.
theforum.sph.harvard.edu/expert-participants/hilary-marston/
24.09.2021
Harvard T.H. Chan School of Public Health
Hilary Marston, MD, MPH ’13 | 2021 Emerging Public Health Professional Award
Director for Global COVID Response on the White House COVID-19 Response Team
Hilary Marston has devoted her career to protecting public health on a global scale, working as a policy advisor in the field of infectious diseases. She joined the National Institute of Allergy and Infectious Diseases (NIAID) in 2013, where she was instrumental in developing and organizing U.S. responses to the Ebola and Zika outbreaks.
In early 2020, Marston became a key figure in the coordination of COVID-19 activities for NIAID and the National Institutes of Health. She also made significant contributions to Operation Warp Speed, the government’s initiative to accelerate COVID-19 vaccines, therapeutics, and diagnostics. In January 2021, Marston joined the U.S. National Security Council as director for medical and biodefense preparedness. Since May, she has served as director for global COVID-19 response on the White House COVID-19 Response Team. In this role, she leads the administration’s work in global distribution of COVID-19 vaccines, including overseeing sharing from the domestic supply and large-scale vaccine purchases for international donation.
youtube.com/watch?v=F2imiiIFzKE
፨
„STOP modRNA“
„STOP COVAX“